Sign in

    Sean (Xun) Lee

    Research Analyst at H.C. Wainwright & Co.

    Sean (Xun) Lee is Vice President of Equity Research at H.C. Wainwright & Co., specializing in biotechnology and healthcare equities, with coverage of companies including Plus Therapeutics, Edap Tms SA, Cytosorbents Corp, and Myomo Inc. Recognized for actionable insights, Lee has consistently published investment recommendations and price targets, with ratings and performance tracked on platforms such as TipRanks, although specific quantitative metrics are not publicly reported. He began his career as a Research Associate at Princeton University in 2010, held analyst roles at Mars and Zacks Investment Research, and joined H.C. Wainwright as an Equity Research Associate in 2015, earning promotion to Vice President in 2020. Lee holds an MBA in Finance from McMaster University, a Master of Biotechnology from the University of Pennsylvania, a Bachelor’s in Biological Engineering from Cornell, and is a CFA Level 3 Candidate.

    Sean (Xun) Lee's questions to MYOMO (MYO) leadership

    Sean (Xun) Lee's questions to MYOMO (MYO) leadership • Q1 2025

    Question

    Sean Lee asked for more color on the key drivers and obstacles within the O&P channel and whether its current growth pace is expected to continue through the second half of the year.

    Answer

    CEO Paul Gudonis characterized the MyoPro as a significant 'white space' growth opportunity for O&P clinics, which operate in a traditionally slow-growth industry. He identified the main 'pull' or challenge as the time commitment required from busy clinicians to complete the necessary certification training. However, he emphasized that the clinics view it as a worthwhile investment for their practice and patients, suggesting continued growth.

    Ask Fintool Equity Research AI